厦门特宝生物工程股份有限公司（以下简称"公司"）于 2024 年 9 月 10 日 召开 2024 年第一次临时股东大会，选举产生了公司第九届董事会成员及第九届 监事会非职工代表监事，其中非职工代表监事与公司职工代表大会选举产生的 职工代表监事共同组成公司第九届监事会。 2024 年 9 月 10 日，公司召开第九届董事会第一次会议，选举产生第九届董 事会董事长及各专门委员会委员，聘任了公司总经理、副总经理、董事会秘书、 财务负责人和证券事务代表；同日，公司召开第九届监事会第一次会议，选举 产生了第九届监事会主席。现将相关情况公告如下： 证券代码：688278 证券简称：特宝生物 公告编号：2024-040 厦门特宝生物工程股份有限公司关于 选举董事长、董事会专门委员会委员、监事会主席 及聘任高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、选举公司第九届董事会董事长 根据《中华人民共和国公司法》（以下简称"《公司法》"）和《厦门特 宝生物工程股份有限公司章程》（以下简称"《公司章程》"） ...

厦门特宝生物工程股份有限公司 （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职）问 题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的意 见》的相关规定（如适用）； 独立董事候选人声明与承诺 本人蒋晓蕙，已充分了解并同意由提名人厦门特宝生物工程股份有限公司董事 会提名为厦门特宝生物工程股份有限公司第九届董事会独立董事候选人。本人公开 声明，本人具备独立董事任职资格，保证不存在任何影响本人担任厦门特宝生物工 程股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规章 及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董事职 责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼 ...

2024 年半年度募集资金存放与实际使用情况的 证券代码：688278 证券简称：特宝生物 公告编号：2024-026 厦门特宝生物工程股份有限公司 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）根据中国证券监督 管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》和《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运 作》等有关规定，编制了 2024 年半年度募集资金存放与实际使用情况专项报 告，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账情况 根据中国证券监督管理委员会《关于同意厦门特宝生物工程股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕2828 号）核准，并经上海 证券交易所"自律监管决定书〔2020〕21 号"批准，公司向社会首次公开发行 人民币普通股（A 股）4,650 万股，每股发行价为 8.24 元，本次募集资金总额 为人民币 38,316.00 万元，根据有关规定 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 20% increase compared to the same period last year[2]. - The company expects a revenue guidance of RMB 1.2 billion for the full year 2024, reflecting a projected growth rate of 25%[2]. - The company's operating revenue for the first half of 2024 reached CNY 1,189,805,069.91, representing a year-on-year increase of 31.68% compared to CNY 903,579,420.87 in the same period last year[16]. - Net profit attributable to shareholders increased by 50.53% to CNY 304,341,868.43, up from CNY 202,178,809.62 in the previous year[16]. - The net profit after deducting non-recurring gains and losses rose by 41.67% to CNY 330,063,876.52, compared to CNY 232,982,206.21 in the same period last year[16]. - The net cash flow from operating activities increased by 42.93% to CNY 72,403,455.12, up from CNY 50,657,896.97 in the previous year[16]. - Basic earnings per share increased by 50% to CNY 0.75, compared to CNY 0.50 in the same period last year[17]. - The company achieved a revenue of 1.19 billion yuan in the first half of 2024, representing a year-on-year growth of 31.68%[55]. - The net profit attributable to shareholders reached 304 million yuan, marking a 50.53% increase compared to the previous year[55]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2024, representing a 25% year-over-year growth[108]. Research and Development - The R&D expenses for new products and technologies increased by 30%, amounting to RMB 150 million in the first half of 2024[2]. - The proportion of R&D investment to operating revenue decreased by 7.07 percentage points to 11.43% from 18.50% in the previous year[17]. - The company’s total R&D investment amounted to 135.98 million CNY, a decrease of 18.64% compared to the previous year, with the proportion of R&D investment to operating income at 11.43%, down by 7.07 percentage points[45]. - The company has established a comprehensive innovation drug research and development system covering the entire process from drug technology development to clinical research and product industrialization[26]. - The company has made significant advancements in its core technologies, including PEG modification and protein drug production platforms, ensuring sustainable drug innovation capabilities[41]. - The company is focusing on enhancing the clinical cure rate for chronic hepatitis B and reducing the risk of liver cancer through innovative research and development[37]. - The company is enhancing its R&D capabilities with a new research facility of over 30,000 square meters, aimed at improving overall R&D strength and efficiency[57]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[2]. - A strategic acquisition of a biotech firm was completed, enhancing the company's product pipeline and expected to contribute an additional RMB 200 million in revenue by 2025[2]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million allocated for this purpose[109]. - The company has initiated a strategic acquisition of a smaller tech firm, expected to close by Q3 2024, which will enhance its product offerings[104]. - The company is committed to maintaining compliance with regulatory requirements to avoid any penalties or legal issues[106]. Product Development and Launches - The company launched a new long-acting interferon product, which is anticipated to capture a significant share of the chronic hepatitis market[2]. - The company has launched five products, including Pegbinterferon, which is the world's first 40kD PEGylated interferon α-2b injection, recognized as a first-class new drug in China[21]. - The product "Paijin," a long-acting human granulocyte colony-stimulating factor, was approved for market launch in June 2023, representing a significant innovation in the treatment of cancer patients[54]. - New product launches are expected to contribute an additional $100 million in revenue for the next fiscal year[105]. - New product development includes the launch of a cutting-edge technology platform expected to generate an additional 300 million in revenue by the end of 2024[125]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk factors section of the report[2]. - The company is committed to enhancing its risk management system to ensure stable operations and continuous innovation in a rapidly evolving technological environment[53]. - The company faces risks related to technological upgrades and potential patent issues that could impact its core competitiveness[60]. - The company is addressing operational risks, including the potential for unsuccessful bids and declining bid prices for its pharmaceuticals[61]. - The company faces risks related to raw material supply, which could impact business operations if suppliers fail to deliver on time[62]. Financial Management and Governance - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board[181]. - The company has committed to enhancing the management and utilization of raised funds to ensure they are used specifically for designated projects, thereby improving operational efficiency and investor returns[117]. - The company will publicly disclose any failure to fulfill commitments made in the IPO prospectus and apologize to shareholders and the public if necessary[122]. - The company has established strict guidelines for share reduction by major shareholders, including limits on the percentage of shares that can be sold within specified timeframes[98]. - The company has committed to providing stable and continuous profit distribution mechanisms for investors, including detailed regulations on cash dividends and stock dividends[117]. Environmental and Social Responsibility - The company has established an environmental management system and passed the ISO14001 audit, enhancing its environmental protection efforts[91]. - The company has implemented real-time monitoring of water pollutants at its discharge points to prevent pollution[91]. - The company received recognition as an environmentally friendly enterprise in Xiamen for 2024, reflecting its commitment to sustainable development[91]. - The company plans to donate 200,000 RMB to support educational initiatives in Sichuan Liangshan Prefecture from April 2024 to December 2026[94]. - The company continues to focus on public welfare projects related to chronic hepatitis B treatment, achieving important results in various initiatives[94].

证券代码：688278 证券简称：特宝生物 公告编号：2024-028 厦门特宝生物工程股份有限公司 2024 年限制性股票激励计划（草案）摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 《厦门特宝生物工程股份有限公司 2024 年限制性股票激励计划（草案）》 （以下简称"本激励计划"或"本计划"）拟向激励对象授予的限制性股票数量 为600.00万股，占本激励计划草案公告时公司股本总额40,680.00万股的1.47%。 其中，首次授予 480.00 万股，占本激励计划草案公告时公司股本总额的 1.18%， 占本次授予权益总额的 80.00%；预留 120.00 万股，占本激励计划草案公告时公 司股本总额的 0.29%，占本次授予权益总额的 20.00%。 一、股权激励计划目的 为了进一步健全公司长效激励机制，吸引和留住优秀人才，充分调动公司核 心团队的积极性，有效地将股东利益、公司利益和核心团队个人利益结合在一起， 使各方共同关注公司的长远发展，在充分保障股东利益的前提下，按照收益与贡 献匹配的 ...

证券代码：688278 证券简称：特宝生物 公告编号：2024-024 厦门特宝生物工程股份有限公司 重要内容提示： 董事持股的基本情况 本次减持计划实施前，厦门特宝生物工程股份有限公司（以下简称"公司"） 董事兰春先生持有公司股份 1,558,134 股，占公司总股本的 0.38%，股份来源于 公司首次公开发行前，已于 2023 年 1 月 17 日解除限售并上市流通。 减持计划的实施结果情况 2024 年 6 月 15 日，公司披露了《董事减持股份计划公告》（公告编号： 2024-022），兰春先生因个人资金需求，计划自 2024 年 7 月 8 日起至 2024 年 10 月 7 日期间通过集中竞价、大宗交易方式合计减持不超过 380,000 股的公司股份， 占公司总股本的比例不超过 0.093%，占其本人本次减持前所持有公司股份数量 不超过 25%。 2024 年 7 月 15 日，公司收到兰春先生出具的《关于股份减持结果的告知函》， 截至本公告出具日，其通过集中竞价方式累计减持公司股份 380,000 股，占公司 总股本的比例为 0.093%。本次减持计划已实施完毕。同时，兰春先生基于对公 司未来发 ...

证券代码：688278 证券简称：特宝生物 公告编号：2024-023 厦门特宝生物工程股份有限公司 关于派格宾新增适应症获得药物临床试验批准通知书 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的关于公司药品派格宾（通用名称： 聚乙二醇干扰素α-2b注射液）新增适应症"原发性血小板增多症"的《药物临床试验 批准通知书》，现将有关情况公告如下： 一、药品基本情况 药品名称：派格宾® 通用名称：聚乙二醇干扰素α-2b注射液 受理号：CXSL2400270 三、对公司的影响及风险提示 根据我国药品注册相关法律法规要求，药物在获得临床试验批准通知书后，尚 需开展临床试验并经国家药监局审评、审批通过后方可生产上市，本次获得药物临 床试验批准对公司近期经营业绩不会产生重大影响。药品研发具有周期长、投入高、 风险大等特点，后续研究进程、研究结果及审批结果等存在诸多不确定性，敬请广 大投资者谨慎决策，注意投资风险。公司 ...

厦门特宝生物工程股份有限公司 关于参加科创板 2023 年度集体业绩说明会 第三期"提质增效重回报"专场的公告 证券代码：688278 证券简称：特宝生物 公告编号：2024-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 14 日（星期二）16:00 前过邮件、电话、传真等 形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者 普遍关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日发布公司 2023 年度报告，为便于广大投资者更全面深入地了解公司 2023 年经 营成果、财务状况、发展理念等事项，公司参与科创板 2023 年度集体业绩说明 会第三期"提质增效重回报"专场，重点交流提质增效重回报的相关举措。此次 活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所上证 路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥545,302,286.89, representing a year-over-year increase of 30.05%[4] - Net profit attributable to shareholders for Q1 2024 was ¥128,807,591.33, reflecting a growth of 53.03% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥146,409,781.65, an increase of 42.90% year-over-year[4] - Basic earnings per share for Q1 2024 was ¥0.32, up by 52.38% from the same period last year[4] - Total operating revenue for Q1 2024 reached ¥545,302,286.89, an increase of 30.1% compared to ¥419,307,024.70 in Q1 2023[19] - Net profit for Q1 2024 was ¥128,807,591.33, representing a 52.9% increase from ¥84,173,127.64 in Q1 2023[20] - Earnings per share for Q1 2024 were ¥0.32, compared to ¥0.21 in Q1 2023, reflecting a 52.4% increase[21] - The company reported a total comprehensive income of ¥128,807,591.33 for Q1 2024, compared to ¥84,173,127.64 in Q1 2023, marking a 52.9% increase[21] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥78,663,848.24, showing a significant increase of 260.06%[4] - In Q1 2024, the company generated operating cash inflow of ¥628,928,052.33, a significant increase from ¥387,126,178.14 in Q1 2023, representing a growth of approximately 62.3%[22] - The net cash flow from operating activities for Q1 2024 was ¥78,663,848.24, compared to ¥21,847,454.23 in Q1 2023, indicating a year-over-year increase of about 259.5%[23] - The company reported cash outflow from operating activities totaling ¥550,264,204.09 in Q1 2024, up from ¥365,278,723.91 in Q1 2023, reflecting a rise of approximately 50.6%[23] - The company’s cash and cash equivalents increased by ¥242,422,225.78 in Q1 2024, compared to an increase of ¥219,539,221.52 in Q1 2023, indicating a growth of about 10.4%[24] - The ending balance of cash and cash equivalents reached ¥655,073,171.04 in Q1 2024, up from ¥519,870,257.78 in Q1 2023, representing an increase of approximately 26.0%[24] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥2,426,913,277.69, a 3.01% increase from the end of the previous year[5] - The company's total assets reached CNY 2.43 billion, up from CNY 2.36 billion in the previous period, indicating a growth of approximately 3.0%[16] - Total liabilities decreased to ¥421,704,343.64 in Q1 2024 from ¥479,685,751.45 in Q1 2023, a reduction of 12.1%[18] - The company's non-current assets totaled CNY 1.09 billion, an increase from CNY 1.02 billion, representing a growth of about 7.5%[16] - The accounts receivable decreased to CNY 394.76 million from CNY 437.81 million, showing a decline of approximately 9.8%[15] Research and Development - R&D investment totaled ¥55,622,956.59, which decreased by 20.66% year-over-year, and accounted for 10.20% of operating revenue, down by 6.52 percentage points[4][5] - Research and development expenses for Q1 2024 were ¥43,575,928.52, an increase of 15.5% from ¥37,712,423.75 in Q1 2023[19] Shareholder Information - The company reported a total of 7,632 shareholders at the end of the reporting period, with the largest shareholder holding 33.94% of the shares[9] - Total equity attributable to shareholders increased to ¥2,005,208,934.05 in Q1 2024, up 6.9% from ¥1,876,401,342.72 in Q1 2023[18] Charitable Contributions - The company donated CNY 8 million to the "China Chronic Hepatitis B Clinical Cure (Everest) Project," with CNY 200,000 donated during the reporting period[13] - The company has committed to donating up to 30,000 doses of Peginterferon to support hepatitis patients, with 10,000 doses already donated[14] - The company has donated CNY 477.4 million to the "Qihang Project" aimed at exploring treatment options for chronic hepatitis B patients[14] - The company has engaged in various charitable donations, totaling CNY 2.56 million in cash donations to various foundations by the end of the reporting period[13] Operating Costs - Total operating costs for Q1 2024 were ¥379,688,432.09, up 24.7% from ¥304,580,777.32 in Q1 2023[19] - Sales expenses rose to ¥241,910,759.84 in Q1 2024, up 30.0% from ¥186,144,235.35 in Q1 2023[19] - The company paid ¥239,962,364.78 in employee compensation in Q1 2024, which is a significant increase from ¥123,793,401.72 in Q1 2023, reflecting a growth of about 93.9%[23] - Tax payments in Q1 2024 amounted to ¥56,272,206.36, compared to ¥24,146,198.04 in Q1 2023, indicating an increase of approximately 133.4%[23] - The company’s cash outflow related to other operating activities was ¥207,741,927.92 in Q1 2024, slightly up from ¥196,536,352.53 in Q1 2023, showing an increase of about 5.4%[23] Product Recognition - The significant increase in operating revenue was attributed to the growing recognition of the product Paigebin among experts and patients, leading to sustained sales growth[8]

国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 2023年度持续督导跟踪报告 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股 份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科创板 上市项目的保荐机构，根据《中华人民共和国证券法》《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自 律监管指引第11号——持续督导》等相关规定，负责特宝生物上市后的持续督导 工作，并出具2023年度持续督导跟踪报告。 | 工作内容 | 序号 | | 持续督导情况 | | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针 | 1 | | 保荐机构已建立并有效执行了持续 督导制度，并制定了相应的工作计 | | 对具体的持续督导工作制定相应的工作计划 | | | | | | | | 划 | | 根据中国证监会相关规定，在持续督导工作开 | 2 | | 保荐机构已与特宝生物签订《持续 | | 始前，与上市公司或相关当事人签署持续督导 | | | 督导协议》，该协议明确了双方在持 | | 协议，明确双方在持续 ...